CSIMarket
 


Mesoblast Ltd  (MESO)
Other Ticker:  
 

Cumulative Mesoblast Ltd's Working Capital Ratio for Trailing Twelve Months Period

MESO's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

MESO Working Capital Ratio for Trailing Twelve Months Period

(Jun 30 2023)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Jun 30 2021)
IV. Quarter
Y / Y Current Liabilities Growth -3.32 % -3.32 % -3.32 % -3.32 % -4.82 %
Y / Y Current Assets Growth -44.91 % -44.91 % -44.91 % -44.91 % 8.55 %
Working Capital Ratio for Trailing Twelve Months Period 0.75 0.89 1.03 1.17 1.31
Total Ranking # 3460 # 3480 # 3815 # 3447 # 3659
Seq. Current Liabilities Growth 0 % 0 % 0 % -3.32 % 0 %
Seq. Current Assets Growth 0 % 0 % 0 % -44.91 % 0 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Jun 30 2023
On the trailing twelve months basis Despite year on year decrease in Mesoblast Ltd's average Current Liabilities to $109 millions, Working Capital Ratio for Trailing Twelve Months Period to 0.75 below company average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 151 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Mesoblast Ltd. While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about MESO
Working Capital Ratio MESO in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 152
Sector # 967
S&P 500 # 3450


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
1.31 1.11 0.75
(Jun 30 2022)   (Jun 30 2023)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Jun 30 2023, within Biotechnology & Pharmaceuticals Industry Working Capital Ratio for Trailing Twelve Months Period
Aceragen Inc   2.06 
Cidara Therapeutics Inc   2.01 
Erytech Pharma S a   2.00 
Ladrx Corporation  1.94 
Acorda Therapeutics Inc   1.90 
Titan Pharmaceuticals Inc   1.90 
Innate Pharma Sa  1.73 
Cyclo Therapeutics Inc   1.67 
Valneva Se  1.62 
Elutia inc   1.55 
Brainstorm Cell Therapeutics inc   1.50 
Protalix Biotherapeutics inc   1.49 
Tracon Pharmaceuticals Inc   1.36 
Champions Oncology Inc   1.34 
Gilead Sciences Inc   1.33 
Eloxx Pharmaceuticals Inc   1.28 
Zivo Bioscience Inc   1.22 
Greenlight Biosciences Holdings Pbc  1.20 
Mink Therapeutics Inc   1.17 
Outlook Therapeutics Inc   1.13 
Armata Pharmaceuticals Inc   1.05 
Sab Biotherapeutics Inc   1.01 
Mesoblast Ltd  0.89 
Novavax inc  0.86 
Agenus Inc  0.83 
10x Capital Venture Acquisition Corp Iii  0.73 
Sorrento Therapeutics Inc   0.64 
Scilex Holding Company  0.59 
Coeptis Therapeutics Holdings Inc   0.50 
Apeiron Capital Investment Corp   0.38 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com